Welcome to Novo Nordisk Science Hub

Are you a healthcare professional?

EASD 2026 28 September - 2 October 2026

Effect of CagriSema on achievement of composite HbA1c and body weight reduction targets in participants with type 2 diabetes: REIMAGINE 1 ​

Sorry! It looks like the page you are trying to access contains materials that are still under embargo. Please come back and check again later.
Keywords
Diabetes
Congress oral presentation
Amylin
CagriSema
PHASE 3 (RCT)